| | Variable | CVD (n = 95) | Non-CVD (n = 155) | value |
| | Sex, M/F | 58/37 | 105/50 | 0.281 | | Age, year | 66 (56–73) | 55 (45–66) | <0.001 | | BMI, kg·m−2 | 24.40 (22.66–27.00) | 24.22 (22.10–26.45) | 0.187 | | WC, cm | 94 ± 10 | 90 ± 10 | 0.004 | | HC, cm | 98 (94–104) | 97 (94–101) | 0.124 | | WHR | 0.94 (0.90–0.98) | 0.93 (0.89–0.96) | 0.054 | | Smokers | 30 (31.58%) | 51 (32.90%) | 0.828 | | Duration of diabetes, year | 10.0 (5.0–20.0) | 4.0 (0.3–10.0) | <0.001 | | HbA1c, % | 9.6 (8.2–11.6) | 10.5 (8.8–12.1) | 0.022 | | FBG, mmol/L | 7.52 (6.19–9.60) | 7.47 (6.24–9.43) | 0.806 | | FCP, ng/mL | 1.28 (0.70–2.00) | 0.99 (0.54–1.70) | 0.074 | | 2hCP, mIU/L | 3.33 (2.21–5.47) | 3.2 (2.19–4.84) | 0.383 | | HOMA-IR | 4.34 (2.37–6.53) | 3.79 (2.01–6.19) | 0.447 | | TG, mmol/L | 1.33 (1.09–2.14) | 1.47 (1.07–2.07) | 0.396 | | TC, mmol/L | 4.00 (3.48–5.17) | 4.82 (4.17–5.60) | <0.001 | | LDL-C, mmol/L | 2.34 ± 0.96 | 2.97 ± 0.92 | <0.001 | | HDL-C, mmol/L | 0.93 (0.77–1.19) | 0.96 (0.84–1.13) | 0.342 | | UA, μmol/L | 334.8 (267.5–428.1) | 333.7 (271.8–403.8) | 0.805 | | eGFR, ml/min/1.73 m2 | 97 (83–109) | 109 (92–117) | <0.001 | | DR | 28 (29.47%) | 31 (20.00%) | 0.087 | | DN | 17 (17.89%) | 8 (5.16%) | 0.001 | | Hypertension | 69 (72.63%) | 57 (36.77%) | <0.001 | | TNC, pg/mL | 144.51 (122.99–182.47) | 127.24 (108.07–142.65) | <0.001 | | Alarin, pg/mL | 126.59 (105.95–152.63) | 107.90 (98.37–126.21) | <0.001 |
|
|
CVD, cardiovascular diseases; M/F, male/female; BMI, body mass index; WC, waist circumference; HC, hip circumference; WHR, waist-hip ratio; HbA1c, glycated hemoglobin; FBG, fasting blood glucose; FCP, fasting C-peptide; 2hCP, 2 h postprandial C-peptide; HOMA-IR, homeostasis model assessment of insulin resistance index; TG, triglycerides; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; UA, uric acid; eGFR, estimated glomerular filtration rate; DR, diabetic retinopathy; DN, diabetic nephropathy; TNC, tenascin-C.
|
